TABLE 3.
Characteristics of all intervention studies with synbiotics included in the review1
| Authors | Age | Country | Health status | Children receiving antibiotics | Intervention duration | Synbiotic intervention | Control | Vehicle | Growth as a primary or secondary outcome |
|---|---|---|---|---|---|---|---|---|---|
| Famouri et al. (55) | 12–54 mo | Iran | Failure to thrive | Not described | 6 mo | 1.5 × 108 spore B. coagulans + 100 mg FOSs (n = 42) | Placebo (n = 42) | Starch powder | Primary |
| Firmansyah et al. (56) | 12 mo | Indonesia | Healthy | Excluded | 4 mo | 5.8 × 108 CFU B. longum BL999 + 1.2 × 109 CFU L. rhamonosus LPR + 2.5 g linoleic acid + 0.3 mg linolenic acid + 13.8 mg AA + 13.2 mg DHA + 0.6 g inulin + 1.4 g FOSs/d (n = 199) | Placebo (n = 194) | Cow milk–based drink | Primary |
| Kosuwon et al. (57) | 1–3 y | Thailand | Healthy | Included (68% received antibiotics since birth) | 12 wk | 1.1 × 1010 CFU Bifidobacterium breve M-16V + 5.4 g scGOSs + 0.6 g lcFOSs/d (n = 60) | Placebo (n = 59) | Young child formula | Secondary |
| Sazawal et al. (58) | 1–4 y | India | Not described | Included | 1 y | 1.6 × 107 CFU Bifidobacterium lactis HN019 + 2.4 g prebiotic oligosaccharides per day (n = 257) | Placebo (n = 245) | Milk powder | Secondary |
1AA, arachidonic acid; FOS, fructo-oligosaccharide; lcFOS, long-chain fructo-oligosaccharide; scGOS, short-chain galacto-oligosaccharide.